Prior to co-founding Beryllium in 2009 I co-founded Pod Holding Ltd (Pod Investment) in 2000 and served as its Managing Partner until 2008. During my 8 years at Pod I served as lead partner on investment activities for a number of companies, including the cancer company, Pintex Pharmaceuticals and the anti-infectives company Paratek Pharmaceuticals (PRTK)…Read More

I started working at MediChem Life Sciences, a drug discovery and technology company, in a finance role when I graduated from college. deCODE Genetics acquired MediChem three years later, and I stayed on as vice president of finance at the Icelandic company’s U.S. office. Later, I became chief financial officer of Emerald Bio when the company spun out from deCODE in 2009 …Read More

As head of research, I utilize my expertise from my time in academia, big pharma, biotech startups and my own consulting firm to lay the groundwork for our company’s future drug discovery methods and breakthroughs. Before joining Beryllium, I founded ALN Associates, a life sciences consultancy…Read More

With over a decade of industry expertise, I have been at the forefront of numerous, successful structure determination research collaborations, including hepatitis C virus (HCV), oncology and diabetes targets. Prior to joining Beryllium, I was a crystallographer and senior research scientist at the Seattle Structural Genomics Center for Infectious Disease (SSGCID)…Read More

I bring to Beryllium Discovery over 20 years of experience leading diverse functional groups and driving forward-thinking life science teams. As Founder of Blue Sky BioServices I served the company and all stakeholders as CEO and Chief Commercial Officer for 11 years. Over that period I had the privilege to lead Blue Sky from 2 to 45 employees and grew shareholder value 5-fold…Read More